This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters to the Editor

Dr. Addington and Colleagues reply to Methodological Issues in a Comparative Study of Ziprasidone and Risperidone Methodological Issues in a Comparative Study of Ziprasidone and Risperidone

Donald E. N. Addington, MBBS, MRCPsych, FRCPC; Christos Pantelis, MB, BS, MRCPsych, FRANZCP; Antony D. Loebel, MD; and Steven J. Romano, MD

Published: January 16, 2006

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: We appreciate the interest in our research shown by Dr. Gharabawi and the medical affairs team at Janssen Pharmaceutica.

Dr. Gharabawi and colleagues have raised 2 main points: risperidone dose and selection of the population for evaluation of efficacy and safety. Mean total daily doses were 7.4 mg and 114.2 mg for risperidone and ziprasidone, respectively.1‘ ‹

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 67

Quick Links: Dementia , Neurologic and Neurocognitive

Sign-up to stay
up-to-date today!


Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...